Your session is about to expire
← Back to Search
Pegloticase 8 MG/ML [Krystexxa] for Type 2 Diabetes (ULTRA-T2D Trial)
ULTRA-T2D Trial Summary
This trial is testing a medication to see if it can help improve marker of cardiorenal health by lowering uric acid levels in young adults with type 2 diabetes.
- Type 2 Diabetes
- Diabetes
- Diabetic Kidney Disease
- High Uric Acid
ULTRA-T2D Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 35 Patients • NCT03303989ULTRA-T2D Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there still capacity for new participants in this medical experiment?
"Affirmative. Clinicaltrials.gov contains information that suggests this medical trial is in search of individuals to participate. It was initially posted on January 1st 2020 and modified most recently on February 1st 2022; 10 patients are needed from a single location for the duration of the study."
How many participants are recruited for this research program?
"Indeed, per the information on clinicaltrials.gov, this research is actively searching for participants. This investigation was commenced on 1/1/2020 and has been modified most recently on 2/1/2022. The trial requires 10 people to be recruited across a single site."
What previous experiments have analyzed the effects of Pegloticase 8 MG/ML [Krystexxa]?
"Currently, there are four operational clinical trials researching the effects of Pegloticase 8 MG/ML [Krystexxa] across 57 different locations. None are in Phase 3 and most occur in Aurora, Colorado."
Do the entry criteria of this trial exclude persons aged 35 or above?
"As per the requirements set out in this study's eligibility criteria, only participants between 18 and 25 years of age can be considered for enrollment."
Who is eligible to join this research project?
"This experiment seeks 10 volunteers, all between the ages of 18 and 25, who have been clinically diagnosed with hyperuricemia. To be eligible for inclusion in this study, participants must fulfill a set criteria: male gender identity; age range of 18 to 25 years old; diagnosis received before their 21st birthday; serum uric acid levels at or above 5 mg/dl."
Has Krystexxa [Pegloticase 8 MG/ML] achieved regulatory authorization?
"Given the Phase 2 clinical trial status of Pegloticase 8 MG/ML [Krystexxa], our team at Power awarded it a safety rating of 2, as there is evidence to support its protection but not yet enough to prove efficacy."
Share this study with friends
Copy Link
Messenger